Blood methanethiol in alcoholic liver disease with and without hepatic encephalopathy

C J McClain,* L Zieve, W M Doizaki, S Gilberstadt, and G R Onstad

From the Department of Medicine, Minneapolis Veterans Hospital and Hennepin County Medical Center, University of Minnesota, Minneapolis, Minnesota, USA

SUMMARY Blood methanethiol and ammonia concentrations were measured in 16 healthy volunteers, 52 consecutive alcoholic cirrhics without overt hepatic encephalopathy (HE), and 42 consecutive patients with alcoholic liver disease and overt HE. The mean concentration of blood methanethiol was significantly greater than normal in the cirrhics without overt HE, and the means of both methanethiol and ammonia were significantly greater in the patients with than in those without overt HE. Only one patient with overt HE had both normal ammonia and methanethiol blood concentrations. Twenty of the patients with HE were followed serially. The directions of change in methanethiol and ammonia were consistent with the direction of change in mental status in 85% and 60%, respectively. All of the patients who deteriorated and died had changes in blood methanethiol that correlated with the change in mental status. We conclude that blood methanethiol is a valuable adjunct to the ammonia determination in the evaluation of the patient with possible HE. It is especially helpful in following the course of a patient with hepatic encephalopathy, both as to prognosis and as an indicator of response to therapy.

Mercaptans are extremely toxic sulphur-containing compounds that appear to be largely derived from colonic bacterial metabolism of methionine. Like ammonia, mercaptans are normally efficiently removed by the liver but escape detoxification with hepatic failure or shunting of intestinal blood around the liver. Animal studies have shown that small amounts of mercaptans can cause reversible coma and can act synergistically with ammonia and fatty acids to enhance the toxicity of these substances. In 1955, Challenger and Walshe established the association of mercaptans with hepatic failure by isolating methanethiol (methyl mercaptan) from the urine of a woman in deep hepatic coma, and, in 1970, Chen and his colleagues reported a four-fold increase in breath methanethiol in patients with hepatic failure. Recently, a method for measuring mercaptans was developed that was sufficiently sensitive to detect methanethiol in the blood of patients for the first time. We have applied this method to patients with hepatic failure over the past two years and are now reporting the results of this initial experience.

Methods

Simultaneous measurements of blood ammonia and methanethiol were made in 16 healthy hospital employees, 52 consecutive hospitalised patients with alcoholic cirrhosis who did not have overt hepatic encephalopathy (HE), and 42 consecutive hospitalised patients with alcoholic liver disease who had overt encephalopathy. Of the latter patients with encephalopathy, all but four had cirrhosis, the remainder alcoholic hepatitis without cirrhosis. Twenty of the 42 patients with overt HE were followed serially—that is, evaluated with clinical ratings of severity of the encephalopathy and simultaneous measurements of blood ammonia and methanethiol three or four times during the course of their hospitalisation. The intervals between examinations varied from case to case. Encephalopathy was graded by a modification of the criteria of Parsons-Smith et al. as follows: grade 0—no detectable abnormality at bedside examination. Grade I—trivial lack of awareness, euphoria, or apathy; shortened attention span, irritability, restlessness. Grade II—general worsening of grade I, personality change, lethargy, mild neurological changes (especially asterixis). Grade III—confusion, disorientation, somnolence. Grade IV—coma, responsive or un-
Methanethiol in alcoholic liver disease

Table 1  Some characteristics of the patients with liver disease

<table>
<thead>
<tr>
<th></th>
<th>No HE</th>
<th>HE</th>
<th>HE followed serially</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>52</td>
<td>42</td>
<td>20</td>
</tr>
<tr>
<td>Age (yr)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>55 ± 9</td>
<td>55 ± 8</td>
<td>53 ± 7</td>
</tr>
<tr>
<td>Range</td>
<td>26-71</td>
<td>40-79</td>
<td>40-67</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% male</td>
<td>96</td>
<td>95</td>
<td>95</td>
</tr>
<tr>
<td>Liver biopsy available %</td>
<td>80</td>
<td>83</td>
<td>90</td>
</tr>
<tr>
<td>Previous HE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>%</td>
<td>27</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Bilirubin (μmol/l)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>34 ± 34</td>
<td>258 ± 214</td>
<td>222 ± 178</td>
</tr>
<tr>
<td>% ≤ 4.0</td>
<td>85</td>
<td>26</td>
<td>30</td>
</tr>
<tr>
<td>% &gt; 4.0</td>
<td>15</td>
<td>74</td>
<td>70</td>
</tr>
<tr>
<td>Albumin (g/l)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>34 ± 6</td>
<td>28 ± 7</td>
<td>28 ± 7</td>
</tr>
<tr>
<td>% ≤ 3.0</td>
<td>27</td>
<td>68</td>
<td>60</td>
</tr>
<tr>
<td>Prothrombin time (s)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>13.6 ± 1.5</td>
<td>16.0 ± 2.6</td>
<td>15.9 ± 2.6</td>
</tr>
<tr>
<td>% &gt; 14</td>
<td>36</td>
<td>76</td>
<td>85</td>
</tr>
<tr>
<td>Ascites</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>%</td>
<td>45</td>
<td>78</td>
<td>75</td>
</tr>
<tr>
<td>Died</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>%</td>
<td>0</td>
<td>60</td>
<td>65</td>
</tr>
</tbody>
</table>

The recovery curves were fairly reproducible. Repeat determinations on individual blood samples varied by as much as 15%, the average being 6.1 ± 3.6% (mean ± SD). One hundred blood samples kept frozen were later run using the flame photometric sulphur-specific detector. The correlation between the two procedures was 0.97. The actual values with the sulphur detector were slightly higher; the average difference, however, was only 8.2 ± 6.7%.

Ten of the 52 patients without overt hepatic encephalopathy, unselected except for convenience of study, were retested one week later in order to evaluate the variability of blood ammonia and methanethiol in patients showing no significant change in clinical status. Table 2 gives the test-retest values for blood ammonia and methanethiol. The mean values show no significant change. However, individual values of both measurements, particularly the blood ammonia, varied considerably. Thus the average of the absolute differences (disregarding signs) between the test-retest values of blood ammonia was 30 ± 19 nmol/ml (mean ± SD), and the upper 95% confidence limit (mean ± 2SD) for the absolute differences was 69 nmol/ml, or 78% of the span of normal. Likewise the average of the absolute differences between the test-retest values of blood methanethiol was 51 ± 34 pmol/ml, and the upper 95% confidence limit was 119 pmol/ml, or 22% of the span of normal.

Results

Mean concentrations of both blood ammonia and methanethiol were significantly increased in patients with HE when compared with healthy volunteers (t > 5.5, p < 0.001) and cirrhotics without overt HE (t > 4.5, p < 0.001). Mean concentrations of both blood ammonia and methanethiol were increased in patients with and without HE are shown in Fig. 2. The correlation between the two measurements in these patients is insignificant. The outward distribution in the two-dimensional plot of the cases with overt HE, and the overlap between groups is apparent. The highest blood methanethiol concentration was 2110
pmol/ml, and the highest blood ammonia 235 nmol/ml. In the absence of overt HE, blood ammonia was abnormal in 13% of patients, methanethiol in 64%, and one or the other in 67%. In the presence of overt HE blood ammonia was abnormal in 48% of patients, methanethiol in 93%, and one or the other in 98%. Thus, with either type of patient, the incidence of abnormal values of methanethiol was significantly greater than with ammonia \( (p<0.001) \). Among patients without overt HE only 8% had methanethiol values of 1000 pmol/ml or more, and 15% values of 800 pmol/ml or more. In contrast, in those patients with overt HE, 43% had blood methanethiol of 1000 pmol/ml or more and...
60% values of 800 pmol/ml or more. Only 7% of these patients had a blood methanethiol value of less than 600 pmol/ml, while 48% of the patients without HE had values below 600 pmol/ml. These differences between the patients with and without HE were highly significant (p<0.001).

Of the 20 patients with HE who had serial measurements, seven showed improvement in their encephalopathy and survived. Fig. 3 shows blood ammonia and methanethiol values of these patients expressed as a percentage of their upper normal limits (90 nmol/ml and 550 pmol/ml respectively). The values at each patient's worst and best mental state are connected by a line indicating the direction of change in encephalopathy. In these patients all but one ammonia value decreased, consistent with the change in mental state. However, based upon the 95% confidence limits derived from the test-retest determinations in the 10 clinically stable cirrhotics, none of the individual changes was significant. Three of the methanethiol changes (patients 1, 3, and 7) were also insignificant. The methanethiol values in patients 2 and 6 increased as encephalopathy improved. Protein starvation before admission to hospital may have depressed their initial methanethiol values.

The remaining 13 patients who were followed serially died of their disease. Figure 4 shows the vectors in these patients. In six of the 13, changes in both blood ammonia and methanethiol were consistent with the clinical changes in mental state. However, inconsistencies between ammonia and methanethiol in individual patients occurred. Thus patients 1, 2, and 5 had comparatively much higher methanethiol than ammonia values, and patient 6 had a preterminal ammonia value that was much higher, relatively, than his methanethiol value, which was practically unchanged. In seven of the patients, changes in blood ammonia, unlike methanethiol, were not consistent with the clinical changes in mental state. All seven patients had preterminal ammonia values less than the initial value when the clinical estimate of encephalopathy was at least two grades lower, though most of the individual changes were not significant. None of the methanethiol values decreased in these patients, though the change in patient 11 was probably insignificant and certainly not commensurate with the change in clinical severity. Considering the entire group of 13 patients who died, the average ammonia value when the encephalopathy was the least was 95±15 nmol/ml (mean±SEM), and when the encephalopathy was the worst it was 104±16 nmol/ml. The average difference of 10±19 nmol/ml was insignificant (t=0.53, P>0.6). The corresponding values for methanethiol were 746±72 pmol/ml and 1211±128 pmol/ml. The average difference of 465±92 was significant (t=5.1, P<0.001).

Of the 20 patients with serial measurements, 17 (85%) had directional changes in methanethiol and 12 (60%) directional changes in ammonia that were consistent with the direction of clinical change. Among the 13 patients who died in hepatic coma, all had directional changes in methanethiol that were similar to the direction of clinical change. If changes among the entire group of 20 patients were only counted when they exceeded the 95% confidence limits derived from the test-retest determinations in the 10 clinically stable cirrhotics, only 13 (65%) had methanethiol and three (15%) ammonia changes that were consistent with the clinical change. The difference between 65% and 15% was significant (p<0.01) by the Chi-squared test corrected for small numbers.

**Discussion**

In any relatively unselected sample of patients with liver disease such as ours, the more severe the hepatic...
failure the more likely that encephalopathy will occur. Thus, the presence of hepatic encephalopathy is usually an indication in itself of severe liver disease. The ordinary tests of liver function do not differentiate the patients with encephalopathy from those without encephalopathy. Some measurements such as the blood ammonia and certain plasma amino acids will do so inefficiently, there being great overlap among groups. No measurement has yet been found that will completely separate patients with encephalopathy from those without encephalopathy, and it is not likely that such complete separation will ever be achieved. The blood methanethiol is simply an additional measurement like ammonia that reflects both hepatic dysfunction and the extent to which blood from the intestine bypasses the liver. As a liver function test it differentiates patients with liver disease from those without liver disease. The magnitude of its abnormality is what differentiates those with from those without encephalopathy. The blood methanethiol concentration appears to correlate at least as well as the blood ammonia with the development of HE. Having both measurements is more useful then either one alone. We look upon the blood methanethiol measurement as an adjunct to the blood ammonia in the quantitative evaluation of a patient with possible HE. An isolated determination of either of these measurements at one point in the patient’s course may not be clinically useful. However, serial measurements are helpful in following the patient with HE, particularly as an indicator of response to therapy. Like ammonia, methanethiol may also play a pathogenetic role in HE. Evidence for this comes from both animal experiments and human studies.

Methanethiol administered by injection or inhalation produces reversible coma in rats. Similarly, feeding of methionine to shunted dogs produces reversible coma as does intravenous administration of methanethiol. Methanethiol acts synergistically with both ammonia and fatty acids, enhancing the toxicity of each. Thus, subcoma doses of methanethiol administered with subcoma amounts of either fatty acids or ammonia produced coma in experimental animals. Blood levels of methanethiol in rats with experimentally produced fulminant hepatic failure and coma were similar in magnitude to those observed in patients with hepatic coma. The concentration of methanethiol in the brain of such rats in hepatic coma was increased five-fold. The mechanism of methanethiol-induced coma is unclear. Waller demonstrated methanethiol inhibition of mitochondrial respiration in rat livers. Methanethiol has also been shown to reversibly inhibit brain microsomal (Na⁺, K⁺)-ATPase. Both these actions may be involved in the pathogenesis of HE, but addi-

tional work in this area is required.

In man, methanethiol has been indirectly implicated as a cause of hepatic encephalopathy. Because methionine deficiency caused hepatic injury in rats, methionine supplementation was once considered to be therapeutic for patients with hepatic decompensation. Then Watson and Kinsell et al. reported patients with cirrhosis who developed confusion and disorientation after methionine administration. Subsequent studies by Phear and coworkers showed that oral methionine ingestion caused HE in many chronic cirrhotics. Neuropsychiatric deterioration occurred without significant increase in blood ammonia levels and the toxic effects were blocked by a broad spectrum antibiotic. It was concluded that the deleterious effect of methionine was due to some toxic breakdown product of methionine other than ammonia.

These observations were clarified by Chen and coworkers who found that the concentration of dimethyl sulphide in the breath of cirrhotics who were treated with methionine was related to both the intensity of breath odour and the encephalopathy that resulted. Dimethyl sulphide is rapidly formed from methanethiol, being its primary metabolic derivative. Like methanethiol, dimethyl sulphide has been shown to produce reversible coma in rats. Thus, natural products of methionine breakdown in the gut, methanethiol and dimethyl sulphide, could be related to the encephalopathic effects observed in cirrhotics ingesting an excess of methionine. It is also possible that reducing methionine in the diet may be beneficial to such patients. Greenberger and associates successfully used a vegetable protein diet low in methionine to treat patients with particularly severe chronic portal systemic encephalopathy, though they did not establish that the beneficial effect was due to the reduction in methionine. Finally, we now report blood levels of methanethiol that are significantly higher in cirrhotics with overt encephalopathy than in those without overt encephalopathy.

It is thus reasonable to postulate a pathogenetic role for methanethiol in hepatic encephalopathy, and we think that measurements of blood mercaptans will have significance as indicators of both the presence of HE and of one of the pathogenic factors.

We are indebted to Nadine Steel for excellent technical assistance.

References

1 Zieve L, Doizaki WM, Zieve FJ. Synergism between mercaptans and ammonia or fatty acids in the production of coma: a possible role for mercaptans in the

McClain, Zieve, Doizaki, Gilberstadt, and Onstad
Methanethiol in alcoholic liver disease

Blood methanethiol in alcoholic liver disease with and without hepatic encephalopathy.

C J McClain, L Zieve, W M Doizaki, S Gilberstadt and G R Onstad

Gut 1980 21: 318-323
doi: 10.1136/gut.21.4.318

Updated information and services can be found at:
http://gut.bmj.com/content/21/4/318

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Alcoholic liver disease (127)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/